- Home
- CLLS vs EPRX Comparison
CLLS vs EPRX Comparison
Compare CLLS & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- EPRX
- Stock Information
- Founded
- CLLS 1999
- EPRX 2011
- Country
- CLLS France
- EPRX Canada
- Employees
- CLLS N/A
- EPRX N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- EPRX
- Sector
- CLLS Health Care
- EPRX
- Exchange
- CLLS Nasdaq
- EPRX NYSE
- Market Cap
- CLLS 148.1M
- EPRX 130.0M
- IPO Year
- CLLS 2007
- EPRX N/A
- Fundamental
- Price
- CLLS $1.45
- EPRX $3.29
- Analyst Decision
- CLLS Buy
- EPRX Strong Buy
- Analyst Count
- CLLS 3
- EPRX 1
- Target Price
- CLLS $7.00
- EPRX $9.00
- AVG Volume (30 Days)
- CLLS 120.5K
- EPRX 8.3K
- Earning Date
- CLLS 05-27-2025
- EPRX 05-07-2025
- Dividend Yield
- CLLS N/A
- EPRX N/A
- EPS Growth
- CLLS N/A
- EPRX N/A
- EPS
- CLLS N/A
- EPRX N/A
- Revenue
- CLLS $49,217,000.00
- EPRX N/A
- Revenue This Year
- CLLS $1.26
- EPRX N/A
- Revenue Next Year
- CLLS N/A
- EPRX N/A
- P/E Ratio
- CLLS N/A
- EPRX N/A
- Revenue Growth
- CLLS 435.38
- EPRX N/A
- 52 Week Low
- CLLS $1.10
- EPRX $2.20
- 52 Week High
- CLLS $3.38
- EPRX $4.48
- Technical
- Relative Strength Index (RSI)
- CLLS 60.38
- EPRX N/A
- Support Level
- CLLS $1.40
- EPRX N/A
- Resistance Level
- CLLS $1.56
- EPRX N/A
- Average True Range (ATR)
- CLLS 0.09
- EPRX 0.00
- MACD
- CLLS 0.03
- EPRX 0.00
- Stochastic Oscillator
- CLLS 76.09
- EPRX 0.00
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.